UA74648C2 - Disintegration means for dry powder inhalers and inhaler itself - Google Patents

Disintegration means for dry powder inhalers and inhaler itself Download PDF

Info

Publication number: UA74648C2
Authority: UA; Ukraine
Prior art keywords: chamber; particles; air; flow; carrier
Prior art date: 2001-06-22

Application number

UA20031211618A

Other languages

English (en)

Ukrainian (uk)

Inventor

Anne Haaije De Boer

Henderik Willem Frijlink

Original Assignee

Sofotech Gmbx & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2002-06-15

Publication date

2006-01-16

2002-06-15 Application filed by Sofotech Gmbx & Co Kg filed Critical Sofotech Gmbx & Co Kg

2006-01-16 Publication of UA74648C2 publication Critical patent/UA74648C2/uk

Links

239000000843 powder Substances 0.000 title abstract description 128
239000002245 particle Substances 0.000 abstract description 253
239000000203 mixture Substances 0.000 abstract description 128
238000000034 method Methods 0.000 abstract description 9
238000009472 formulation Methods 0.000 abstract 1
239000003814 drug Substances 0.000 description 110
229940079593 drug Drugs 0.000 description 102
239000008187 granular material Substances 0.000 description 61
239000010419 fine particle Substances 0.000 description 51
238000013461 design Methods 0.000 description 50
230000014759 maintenance of location Effects 0.000 description 47
239000000853 adhesive Substances 0.000 description 46
230000001070 adhesive effect Effects 0.000 description 46
239000013078 crystal Substances 0.000 description 41
238000000926 separation method Methods 0.000 description 27
230000000694 effects Effects 0.000 description 23
210000000214 mouth Anatomy 0.000 description 23
239000000243 solution Substances 0.000 description 22
238000002156 mixing Methods 0.000 description 21
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 20
239000002775 capsule Substances 0.000 description 20
210000004027 cell Anatomy 0.000 description 19
230000009471 action Effects 0.000 description 17
229960001375 lactose Drugs 0.000 description 17
239000008101 lactose Substances 0.000 description 17
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
238000005054 agglomeration Methods 0.000 description 16
230000002829 reductive effect Effects 0.000 description 16
239000000443 aerosol Substances 0.000 description 15
230000002776 aggregation Effects 0.000 description 15
210000003800 pharynx Anatomy 0.000 description 13
230000009467 reduction Effects 0.000 description 13
230000008901 benefit Effects 0.000 description 12
230000003993 interaction Effects 0.000 description 12
230000036961 partial effect Effects 0.000 description 12
238000010276 construction Methods 0.000 description 11
230000006870 function Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
238000012986 modification Methods 0.000 description 11
210000002345 respiratory system Anatomy 0.000 description 11
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 10
229960004436 budesonide Drugs 0.000 description 10
238000010586 diagram Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
230000001133 acceleration Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000000969 carrier Substances 0.000 description 8
230000006378 damage Effects 0.000 description 8
230000008021 deposition Effects 0.000 description 8
238000005755 formation reaction Methods 0.000 description 8
230000000717 retained effect Effects 0.000 description 8
238000009825 accumulation Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000007423 decrease Effects 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
238000009826 distribution Methods 0.000 description 7
238000011068 loading method Methods 0.000 description 7
238000005259 measurement Methods 0.000 description 7
239000011505 plaster Substances 0.000 description 7
238000003860 storage Methods 0.000 description 7
238000010408 sweeping Methods 0.000 description 7
230000008859 change Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000011164 primary particle Substances 0.000 description 6
238000004062 sedimentation Methods 0.000 description 6
108010078777 Colistin Proteins 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000004888 barrier function Effects 0.000 description 5
238000005520 cutting process Methods 0.000 description 5
238000000227 grinding Methods 0.000 description 5
125000006850 spacer group Chemical group 0.000 description 5
229930195727 α-lactose Natural products 0.000 description 5
239000012876 carrier material Substances 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000945 filler Substances 0.000 description 4
230000005484 gravity Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000021715 photosynthesis, light harvesting Effects 0.000 description 4
230000035939 shock Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
230000007704 transition Effects 0.000 description 4
206010007134 Candida infections Diseases 0.000 description 3
206010013952 Dysphonia Diseases 0.000 description 3
208000010473 Hoarseness Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
239000013543 active substance Substances 0.000 description 3
238000012387 aerosolization Methods 0.000 description 3
201000003984 candidiasis Diseases 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
229960001127 colistin sulfate Drugs 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
230000007547 defect Effects 0.000 description 3
229940112141 dry powder inhaler Drugs 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000006260 foam Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007794 irritation Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000007774 longterm Effects 0.000 description 3
ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 3
238000005457 optimization Methods 0.000 description 3
238000005192 partition Methods 0.000 description 3
239000011148 porous material Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000007790 scraping Methods 0.000 description 3
241000222122 Candida albicans Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960003346 colistin Drugs 0.000 description 2
239000004567 concrete Substances 0.000 description 2
238000012937 correction Methods 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000011888 foil Substances 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000003434 inspiratory effect Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000004804 winding Methods 0.000 description 2
FHYAUNJNVMGZQN-NHCUHLMSSA-N (2r,3r)-5-iodo-3-(4-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1CN([C@@H]2CC3=C(I)C=CC=C3C[C@H]2O)CCC1C1=CC=CC=C1 FHYAUNJNVMGZQN-NHCUHLMSSA-N 0.000 description 1
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
244000293889 Bombax malabaricum Species 0.000 description 1
235000004480 Bombax malabaricum Nutrition 0.000 description 1
241000283707 Capra Species 0.000 description 1
244000037364 Cinnamomum aromaticum Species 0.000 description 1
235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
241000272470 Circus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
244000182067 Fraxinus ornus Species 0.000 description 1
235000002917 Fraxinus ornus Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000702691 Homo sapiens Zinc finger protein SNAI1 Proteins 0.000 description 1
241000030781 Ippa Species 0.000 description 1
244000208060 Lawsonia inermis Species 0.000 description 1
206010051602 Laziness Diseases 0.000 description 1
241000283965 Ochotona princeps Species 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
244000007853 Sarothamnus scoparius Species 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
206010049633 Shoshin beriberi Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
238000005411 Van der Waals force Methods 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
102100030917 Zinc finger protein SNAI1 Human genes 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
-1 alpha-lactose monohydrogen Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000002528 anti-freeze Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
238000003287 bathing Methods 0.000 description 1
238000005452 bending Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000037182 bone density Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
239000011362 coarse particle Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003640 drug residue Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
210000000887 face Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005242 forging Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
238000000465 moulding Methods 0.000 description 1
BNGZNZUNROGDHT-UHFFFAOYSA-N n-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide;hydrate Chemical compound O.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 BNGZNZUNROGDHT-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229960004583 pranlukast Drugs 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000023804 progressive myoclonic epilepsy type 7 Diseases 0.000 description 1
KKMLIVYBGSAJPM-UHFFFAOYSA-L propineb Chemical compound [Zn+2].[S-]C(=S)NC(C)CNC([S-])=S KKMLIVYBGSAJPM-UHFFFAOYSA-L 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960005018 salmeterol xinafoate Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000010008 shearing Methods 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
229940126589 solid medicine Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000003746 surface roughness Effects 0.000 description 1
230000002522 swelling effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000023409 throat pain Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
229960001296 zinc oxide Drugs 0.000 description 1
XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc oxide Inorganic materials [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
235000014692 zinc oxide Nutrition 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA20031211618A 2001-06-22 2002-06-15 Disintegration means for dry powder inhalers and inhaler itself UA74648C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10129703A DE10129703A1 (de)	2001-06-22	2001-06-22	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
PCT/EP2002/006610 WO2003000325A1 (en)	2001-06-22	2002-06-15	Powder formulation disintegrating system and method for dry powder

Publications (1)

Publication Number	Publication Date
UA74648C2 true UA74648C2 (en)	2006-01-16

Family

ID=7688810

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20031211618A UA74648C2 (en)	2001-06-22	2002-06-15	Disintegration means for dry powder inhalers and inhaler itself

Country Status (31)

Country	Link
EP (1)	EP1397174B1 (cs)
JP (1)	JP4116537B2 (cs)
KR (1)	KR100904955B1 (cs)
CN (1)	CN100337699C (cs)
AR (1)	AR034616A1 (cs)
AT (1)	ATE477826T1 (cs)
AU (1)	AU2009200071B2 (cs)
BG (1)	BG66589B1 (cs)
BR (2)	BRPI0210026B8 (cs)
CA (1)	CA2445892C (cs)
CY (1)	CY1110924T1 (cs)
CZ (1)	CZ302528B6 (cs)
DE (2)	DE10129703A1 (cs)
DK (1)	DK1397174T3 (cs)
ES (1)	ES2350973T3 (cs)
HK (1)	HK1064313A1 (cs)
HR (1)	HRP20040058B1 (cs)
HU (1)	HU227457B1 (cs)
IL (3)	IL158614A0 (cs)
MX (1)	MXPA03011550A (cs)
NO (1)	NO332992B1 (cs)
NZ (1)	NZ530308A (cs)
PL (1)	PL204900B1 (cs)
PT (1)	PT1397174E (cs)
RU (1)	RU2291717C2 (cs)
SI (1)	SI1397174T1 (cs)
SK (1)	SK288034B6 (cs)
TW (1)	TW567075B (cs)
UA (1)	UA74648C2 (cs)
WO (1)	WO2003000325A1 (cs)
ZA (1)	ZA200308555B (cs)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1488819A1 (en)	2003-06-16	2004-12-22	Rijksuniversiteit te Groningen	Dry powder inhaler and method for pulmonary inhalation of dry powder
RU2258539C1 (ru) *	2004-03-23	2005-08-20	Чучалин Александр Григорьевич	Порошковый ингалятор
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005046645B3 (de) *	2005-09-29	2006-07-20	Braunform Gmbh	Pulverinhalator
DE102005046644B3 (de) *	2005-09-29	2006-07-20	Braunform Gmbh	Pulverinhalator
DE102006007495A1 (de)	2006-02-17	2007-08-23	Siegfried Generics International Ag	Dispergiereinheit
CA2642862A1 (en) *	2006-04-13	2007-10-25	Boehringer Ingelheim Microparts Gmbh	Dispensing device
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2569359T3 (es) *	2007-07-06	2016-05-10	Vectura Delivery Devices Limited	Inhalador
EP2020249A1 (de)	2007-08-01	2009-02-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Inhalator
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
DE102007041720A1 (de) *	2007-09-04	2009-03-05	Alfred Von Schuckmann	Vorrichtung zur Darreichung eines blisterverpackten Medikaments
US8439033B2 (en) *	2007-10-09	2013-05-14	Microdose Therapeutx, Inc.	Inhalation device
EP2230934B8 (en)	2007-12-14	2012-10-24	AeroDesigns, Inc	Delivering aerosolizable food products
PL2082769T3 (pl) *	2008-01-24	2015-12-31	Vectura Delivery Devices Ltd	Inhalator
EP2082764A1 (en) *	2008-01-24	2009-07-29	Boehringer Ingelheim International GmbH	Inhaler
EP2100599A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) *	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2108641A1 (en)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
BRPI0913038A2 (pt) *	2008-05-23	2020-08-18	Otsuka Pharmaceutical Co., Ltd.	inalador de pó
EP2135610A1 (en)	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combination comprising DHODH inhibitors and methotrexate
EP2177521A1 (en)	2008-10-14	2010-04-21	Almirall, S.A.	New 2-Amidothiadiazole Derivatives
EP2196465A1 (en)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2202232A1 (en)	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en)	2009-01-19	2010-07-28	Almirall, S.A.	Oxadiazole derivatives as S1P1 receptor agonists
EP2210615A1 (en)	2009-01-21	2010-07-28	Almirall, S.A.	Combinations comprising methotrexate and DHODH inhibitors
EP2221297A1 (en)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2226323A1 (en)	2009-02-27	2010-09-08	Almirall, S.A.	New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
MX2011009251A (es) *	2009-03-04	2011-11-18	Mannkind Corp	Sistema mejorado de suministro de farmaco en polvo seco.
EP2228368A1 (en)	2009-03-12	2010-09-15	Almirall, S.A.	Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2239256A1 (en)	2009-03-13	2010-10-13	Almirall, S.A.	Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2305660A1 (en)	2009-09-25	2011-04-06	Almirall, S.A.	New thiadiazole derivatives
EP2314577A1 (en)	2009-10-16	2011-04-27	Almirall, S.A.	Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
GB0919465D0 (en) *	2009-11-06	2009-12-23	Norton Healthcare Ltd	Airflow adaptor for a breath-actuated dry powder inhaler
EP2322176A1 (en)	2009-11-11	2011-05-18	Almirall, S.A.	New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2498846A4 (en) *	2009-11-13	2014-08-27	Merck Sharp & Dohme	MEDICINAL PRODUCTS, DRY POWDER INHALATORS AND MULTI-FLUX COLLISION ARRANGEMENTS
EP2343287A1 (en)	2009-12-10	2011-07-13	Almirall, S.A.	New 2-aminothiadiazole derivatives
EP2338888A1 (en)	2009-12-24	2011-06-29	Almirall, S.A.	Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en)	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazole derivatives as jak inhibitors
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2366702A1 (en)	2010-03-18	2011-09-21	Almirall, S.A.	New oxadiazole derivatives
EP2380890A1 (en)	2010-04-23	2011-10-26	Almirall, S.A.	New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2390252A1 (en)	2010-05-19	2011-11-30	Almirall, S.A.	New pyrazole derivatives
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2455080A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2455081A1 (en)	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of crohn's disease
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
US8974450B2 (en)	2011-02-03	2015-03-10	Covidien Lp	System and method for ablation procedure monitoring using electrodes
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2510928A1 (en)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium for use in improving the quality of sleep in respiratory patients
EP2518071A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
EP2526945A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	New CRTH2 Antagonists
EP2527344A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548863A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists.
EP2548876A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
EP2747815B1 (en)	2011-09-07	2017-11-29	Concentrx Pharmaceuticals, Inc.	Dry powder inhalation device
EP2578570A1 (en)	2011-10-07	2013-04-10	Almirall, S.A.	Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592077A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2617448A1 (en)	2012-01-20	2013-07-24	Almirall S.A.	Inhalation device for powdered drugs
EP2617449A1 (en)	2012-01-20	2013-07-24	Almirall S.A.	Inhalation device for powdered drugs
EP2617450A1 (en)	2012-01-20	2013-07-24	Almirall S.A.	Inhaltion device for powdered drugs
EP2641900A1 (en)	2012-03-20	2013-09-25	Almirall, S.A.	Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en)	2012-04-02	2013-10-09	Almirall, S.A.	Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
EP2666465A1 (en)	2012-05-25	2013-11-27	Almirall, S.A.	Novel dosage and formulation
EP2668941A1 (en)	2012-05-31	2013-12-04	Almirall, S.A.	Novel dosage form and formulation of abediterol
WO2014060431A1 (en)	2012-10-16	2014-04-24	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en)	2012-11-28	2014-06-04	Almirall, S.A.	New bicyclic compounds as crac channel modulators
CN104869996A (zh)	2012-12-17	2015-08-26	阿尔米雷尔有限公司	阿地铵的新用途
JP6307091B2 (ja)	2012-12-18	2018-04-04	アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ，Ｓ．Ａ．	β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TW201446767A (zh)	2013-02-15	2014-12-16	Almirall Sa	作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
EP2848615A1 (en)	2013-07-03	2015-03-18	Almirall, S.A.	New pyrazole derivatives as CRAC channel modulators
WO2015091287A1 (en)	2013-12-19	2015-06-25	Almirall S.A.	Dosage formulation comprising salmeterol and fluticasone propionate
EP2944343A1 (en)	2014-05-15	2015-11-18	AstraZeneca AB	Dry powder inhaler
BR112016028324B1 (pt) *	2014-06-06	2021-12-14	Rijksuniversiteit Groningen	Inalador de pó seco acionado pela respiração
MX2017006912A (es) *	2014-11-26	2017-08-15	Vectura Delivery Devices Ltd	Inhalador de polvo seco.
JP2018501903A (ja)	2015-01-14	2018-01-25	レスピラセラピューティクスインコーポレイテッドＲｅｓｐｉｒａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	パウダー分散方法および装置
EP3286178A1 (en)	2015-04-21	2018-02-28	Almirall S.A.	Amino-substituted heterocyclic derivatives as sodium channel inhibitors
WO2016202800A1 (en)	2015-06-16	2016-12-22	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
WO2017076990A1 (en)	2015-11-05	2017-05-11	Almirall, S.A.	Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide
RU2634258C1 (ru) *	2016-11-08	2017-10-24	федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН)	Наполнитель для капсульного ингалятора
US11260184B2 (en) *	2016-11-30	2022-03-01	Philip Morris Products S.A.	Inhaler with sized cavity
EP3600504B1 (en)	2017-03-28	2023-07-12	Concentrx Pharmaceuticals, Inc.	Device for delivering dry powder medicaments
CN107123354B (zh) *	2017-05-21	2019-03-19	谭淞文	分选花形微粒载体的吸入器、呼吸道及肺部模型设备集成
TW201919682A (zh)	2017-08-08	2019-06-01	西班牙商阿爾米雷爾有限公司	活化Ｎｒｆ２路徑的新穎化合物
WO2019159123A1 (en) *	2018-02-19	2019-08-22	Philip Morris Products S.A.	Dry powder inhaler
CN110201279B (zh) *	2018-02-28	2021-05-11	张江	用于吸入给药的药盒和吸入给药组合结构
CN110201281B (zh) *	2018-02-28	2021-08-06	张江	吸入给药装置和吸入给药组合结构
CN110201278B (zh) *	2018-02-28	2021-07-30	张江	用于吸入给药的药盒和吸入给药组合结构
CN110201280B (zh) *	2018-02-28	2021-07-30	张江	用于吸入给药装置的吸嘴和吸入给药装置
CN111514418B (zh) *	2019-06-12	2022-01-14	中南大学湘雅二医院	一种自吸式经鼻粉末材料给送装置
CN111359060A (zh) *	2020-02-20	2020-07-03	深圳麦克韦尔科技有限公司	雾化吸嘴及雾化装置
CN112030136B (zh) *	2020-09-01	2024-12-27	江苏微导纳米科技股份有限公司	镀膜腔体及粉末镀膜装置
CN113750331B (zh) *	2021-08-18	2022-08-16	华中科技大学	一种干粉吸入器
CN114632235B (zh) *	2022-03-04	2023-04-25	华中科技大学	一种干粉吸入器
CN115006656A (zh) *	2022-05-18	2022-09-06	苏州易合医药有限公司	一种可连续提供肺部活性剂粉雾剂的给药装置

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1478138A (en) *	1973-07-18	1977-06-29	Beecham Group Ltd	Device for the administration of powders
IT7920688V0 (it)	1979-02-05	1979-02-05	Chiesi Paolo Parma	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
WO1992003175A1 (en)	1990-08-11	1992-03-05	Fisons Plc	Inhalation device
DE4211475A1 (de) *	1991-12-14	1993-06-17	Asta Medica Ag	Pulverinhalator
DE4239402A1 (de) *	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
DK0674533T3 (da)	1992-12-18	1999-09-27	Schering Corp	Inhalator for medikamenter i pulverform
WO1996010459A2 (en) *	1994-10-04	1996-04-11	Imperial Chemical Industries Plc	Electrostatic spraying of particulate material
CN1181896C (zh) *	1995-06-21	2004-12-29	索福泰克两合公司	带整体计量装置的药筒和药粉吸入器
DE19522416C2 (de) *	1995-06-21	2003-11-20	Sofotec Gmbh & Co Kg	Vorrichtung zum Dispergieren von Pulver in einem Luftstrom zur Verwendung mit Pulver-Inhalatoren
FR2738153B1 (fr) *	1995-09-04	1998-01-02	Valois	Appareil d'inhalation destine a distribuer des doses precises et reproductibles de produit pulverulent
EP1129705A1 (en) *	2000-02-17	2001-09-05	Rijksuniversiteit te Groningen	Powder formulation for inhalation

2001
- 2001-06-22 DE DE10129703A patent/DE10129703A1/de not_active Withdrawn
2002
- 2002-06-12 TW TW091112804A patent/TW567075B/zh not_active IP Right Cessation
- 2002-06-15 SK SK27-2004A patent/SK288034B6/sk unknown
- 2002-06-15 HU HU0400212A patent/HU227457B1/hu unknown
- 2002-06-15 DK DK02780833.6T patent/DK1397174T3/da active
- 2002-06-15 PL PL365946A patent/PL204900B1/pl unknown
- 2002-06-15 KR KR1020037016628A patent/KR100904955B1/ko active IP Right Grant
- 2002-06-15 CN CNB02812121XA patent/CN100337699C/zh not_active Expired - Lifetime
- 2002-06-15 CA CA2445892A patent/CA2445892C/en not_active Expired - Lifetime
- 2002-06-15 PT PT02780833T patent/PT1397174E/pt unknown
- 2002-06-15 RU RU2004102037/14A patent/RU2291717C2/ru active
- 2002-06-15 SI SI200230925T patent/SI1397174T1/sl unknown
- 2002-06-15 NZ NZ530308A patent/NZ530308A/en not_active IP Right Cessation
- 2002-06-15 AT AT02780833T patent/ATE477826T1/de active
- 2002-06-15 BR BRPI0210026A patent/BRPI0210026B8/pt not_active IP Right Cessation
- 2002-06-15 WO PCT/EP2002/006610 patent/WO2003000325A1/en active Application Filing
- 2002-06-15 MX MXPA03011550A patent/MXPA03011550A/es active IP Right Grant
- 2002-06-15 CZ CZ20040046A patent/CZ302528B6/cs not_active IP Right Cessation
- 2002-06-15 EP EP02780833A patent/EP1397174B1/en not_active Expired - Lifetime
- 2002-06-15 BR BR0210026-6A patent/BR0210026A/pt active IP Right Grant
- 2002-06-15 UA UA20031211618A patent/UA74648C2/uk unknown
- 2002-06-15 ES ES02780833T patent/ES2350973T3/es not_active Expired - Lifetime
- 2002-06-15 JP JP2003506966A patent/JP4116537B2/ja not_active Expired - Lifetime
- 2002-06-15 IL IL15861402A patent/IL158614A0/xx unknown
- 2002-06-15 DE DE60237366T patent/DE60237366D1/de not_active Expired - Lifetime
- 2002-06-21 AR ARP020102359A patent/AR034616A1/es active IP Right Grant
2003
- 2003-10-27 IL IL158614A patent/IL158614A/en active IP Right Grant
- 2003-11-03 ZA ZA200308555A patent/ZA200308555B/en unknown
- 2003-12-17 NO NO20035654A patent/NO332992B1/no not_active IP Right Cessation
2004
- 2004-01-06 BG BG108512A patent/BG66589B1/bg unknown
- 2004-01-20 HR HRP20040058AA patent/HRP20040058B1/hr not_active IP Right Cessation
- 2004-09-17 HK HK04107144.6A patent/HK1064313A1/xx not_active IP Right Cessation
2009
- 2009-01-08 AU AU2009200071A patent/AU2009200071B2/en not_active Expired
2010
- 2010-11-17 CY CY20101101039T patent/CY1110924T1/el unknown
2011
- 2011-02-01 IL IL210983A patent/IL210983A/en active IP Right Grant

Also Published As

Publication number	Publication date
CZ302528B6 (cs)	2011-07-07
DE60237366D1 (de)	2010-09-30
BRPI0210026B1 (pt)	2018-04-03
EP1397174B1 (en)	2010-08-18
BRPI0210026B8 (pt)	2021-06-22
CN1541125A (zh)	2004-10-27
IL158614A (en)	2012-12-31
NO20035654D0 (no)	2003-12-17
HRP20040058B1 (hr)	2015-02-27
RU2004102037A (ru)	2005-05-27
ES2350973T3 (es)	2011-01-28
CA2445892A1 (en)	2003-01-03
HU227457B1 (en)	2011-06-28
NZ530308A (en)	2007-01-26
SK272004A3 (sk)	2005-10-06
PT1397174E (pt)	2010-11-10
JP2004530498A (ja)	2004-10-07
BG66589B1 (bg)	2017-07-31
IL210983A0 (en)	2011-04-28
AU2009200071B2 (en)	2011-07-07
HK1064313A1 (en)	2005-01-28
CZ200446A3 (cs)	2005-02-16
WO2003000325A1 (en)	2003-01-03
KR100904955B1 (ko)	2009-06-26
BR0210026A (pt)	2004-04-13
TW567075B (en)	2003-12-21
PL365946A1 (en)	2005-01-24
AR034616A1 (es)	2004-03-03
HUP0400212A2 (en)	2004-06-28
EP1397174A1 (en)	2004-03-17
RU2291717C2 (ru)	2007-01-20
PL204900B1 (pl)	2010-02-26
CA2445892C (en)	2010-08-10
DE10129703A1 (de)	2003-01-02
AU2009200071A1 (en)	2009-02-05
SI1397174T1 (sl)	2010-12-31
KR20040039203A (ko)	2004-05-10
JP4116537B2 (ja)	2008-07-09
ZA200308555B (en)	2004-02-17
DK1397174T3 (da)	2010-12-06
ATE477826T1 (de)	2010-09-15
HRP20040058A2 (en)	2004-08-31
BG108512A (en)	2005-02-28
CN100337699C (zh)	2007-09-19
SK288034B6 (en)	2013-01-02
CY1110924T1 (el)	2015-06-10
MXPA03011550A (es)	2004-03-18
IL158614A0 (en)	2004-05-12
IL210983A (en)	2014-11-30
NO20035654L (no)	2004-02-18
NO332992B1 (no)	2013-02-11

Publication	Publication Date	Title
UA74648C2 (en)	2006-01-16	Disintegration means for dry powder inhalers and inhaler itself
US6681768B2 (en)	2004-01-27	Powder formulation disintegrating system and method for dry powder inhalers
EP0477222B1 (en)	2000-08-16	Device for more effective pulverization of a powdered inhalation medicament
JP6946363B2 (ja)	2021-10-06	吸入可能な薬剤
Islam et al.	2024	Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: Challenges and future strategies
AU2002350483A1 (en)	2003-01-08	Powder formulation disintegrating system and method for dry powder
NZ721338B2 (en)	2022-06-28	Inhalable medicaments
IT9020332A1 (it)	1991-11-17	Nedocromil sodio particellare con un diametro medio massico compreso tra 5 e 10 micrometri